Here are the key details to know:
1. The ibs-smart test measures two antibodies, anti-CdtB and anti-vinculin, in diagnosing diarrhea predominant and mixed-type IBS.
2. Mark PImentel, MD, founder of Gemelli Biotech, led research at Los Angeles-based Cedars-Sinai Hospital that found anti-CdtB and anti-vinculin, were elevated in patients with IBS-D and IBS-M, which supports the theory that a subset of IDB cases start after a patient has food poisoning.
3. “As our scientific understanding of post-infectious IBS and its antibody biomarkers has advanced, we’ve continued to advance the technology used to test the blood for these substances,” Dr. Pimente said. “For example, our ability to manage and measure anti-CdtB has improved through epitope optimization, which has significantly increased the test’s likelihood ratio and overall accuracy.”
4. The ibs-smart test is exclusively licensed by Cedars-Sinai to Gemelli Biotech. Results of the test are available after 48 hours, with a positive result indicating a patient has IBS-D with a positive predictive value greater than 90 percent.
More articles on gastroenterology:
5 must-read articles for GI physicians this week: Oct. 4-10
Former gastroenterology researcher under investigation for child porn, economic espionage — 6 insights
GI leader to know: Dr. Khaled Issa of Cleveland Clinic’s North Ohio Gastroenterology
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
